Skip to main content
TipRanks
Go Ultimate75% OFF

Shilpa Medicare Limited (SHILPAMED) AI Stock Analysis

3 Followers
IN:SHILPAMED

Shilpa Medicare Limited

(NSE:SHILPAMED)

Select Model
Rating:73Outperform
Price Target:INR 1,007.00â–²(1.40% Upside)
Action:reiterated
Date:09/19/26

Score led by robust financial recovery and low-leverage balance sheet plus strong technical momentum above key averages; high P/E valuation tempers the overall result.

Positive Factors
Revenue Growth and Profitability RecoveryThe FY2026 recovery combines renewed revenue growth with materially stronger profitability, indicating improved operating performance rather than growth alone. If these margins remain durable, the company can generate more earnings from expanding sales and support continued investment in complex pharmaceutical products and capabilities.
Negative Factors
Persistent Negative Free Cash FlowPersistent negative free cash flow means reported earnings have not consistently translated into surplus cash after investment needs. This weakens cash-generation quality, can increase reliance on external funding, and may constrain the company’s ability to pursue growth while maintaining financial flexibility.

Shilpa Medicare Limited (SHILPAMED) vs. iShares MSCI India ETF (INDA)

-50%0%50%100%150%200%IN:SHILPAMED+171.62%INDA-5.86%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
INR 193.92B
Dividend Yield
0.06%
Average Volume (3M)
64.29K
Price to Earnings (P/E)
58.3
Beta (1Y)
0.47
Revenue Growth
37.27%
EPS Growth
142.29%
Country
India
Employees
1,132
Sector
General
Sector Strength
55
Industry
Drug Manufacturers - Specialty & Generic

Shilpa Medicare Limited Business Overview & Revenue Model

Company Description

Shilpa Medicare Limited, including its various subsidiaries, manufactures and distributes a range of active pharmaceutical ingredients (APIs), intermediate compounds, and finished drug formulations. Operating across India, the United States, Europe,...

How the Company Makes Money

Shilpa Medicare primarily makes money through (1) sales of pharmaceutical APIs and intermediates to other drug manufacturers, where revenue is earned per unit/contracted supply based on volumes and pricing for specific molecules; (2) sales of finishe...

Shilpa Medicare Limited Financial Statement Overview

Summary

Strong balance sheet with low 0.25 debt-to-equity and equity at 25.91B; revenue grew 14.71% to 15.39B with net income recovery to 2.43B, though negative free cash flow of -0.75B adds risk.

Income Statement

75Positive

Balance Sheet

85Very Positive

Cash Flow

60Neutral
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue18.42B15.39B12.86B11.53B10.43B11.40B
Gross Profit10.11B6.24B8.76B7.10B1.34B7.56B
EBITDA5.18B4.35B3.11B2.46B1.13B2.23B
Net Income3.32B2.43B782.93M318.74M-325.33M606.62M
Balance Sheet
Total Assets41.38B37.06B33.11B30.93B29.04B28.75B
Cash, Cash Equivalents and Short-Term Investments1.11B451.80M585.61M302.26M221.92M338.29M
Total Debt6.66B6.60B5.88B9.37B7.98B6.83B
Total Liabilities13.80B11.14B9.47B12.93B11.30B10.64B
Stockholders Equity27.58B25.91B23.72B18.09B17.83B18.22B
Cash Flow
Free Cash Flow0-754.00M-1.11B-492.22M-467.44M-2.27B
Operating Cash Flow02.95B1.32B1.35B1.80B1.05B
Investing Cash Flow0-3.27B-1.99B-1.67B-2.33B-2.85B
Financing Cash Flow0612.20M626.54M467.75M457.98M828.58M

Shilpa Medicare Limited Technical Analysis

Technical Analysis SentimentPositive
Last Price993.10

Price Trends

50DMA965.39Positive
100DMA827.66Positive
200DMA612.19Positive

Market Momentum

MACD2.79Negative
RSI59.72Neutral
STOCH74.91Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:SHILPAMED, the sentiment is Positive. The current price of 993.10 is above the 20-day moving average (MA) of 921.57, above the 50-day MA of 965.39, and above the 200-day MA of 612.19, indicating a bullish trend. The MACD of 2.79 indicates Negative momentum. The RSI at 59.72 is Neutral, neither overbought nor oversold. The STOCH value of 74.91 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:SHILPAMED.

Shilpa Medicare Limited Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

IN:SHILPAMED against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IN:CAPLIPOINTIN:CAPLIPOINT85OutperformINR 181.40B26.35―0.34%16.84%17.02%
IN:STARIN:STAR74OutperformINR 93.51B15.16―0.49%11.28%55.18%
IN:AKUMSIN:AKUMS73OutperformINR 116.56B31.19―0.40%17.50%14.74%
IN:SHILPAMEDIN:SHILPAMED73OutperformINR 194.23B58.32―0.06%37.27%142.29%
IN:APLLTDIN:APLLTD71OutperformINR 202.40B24.00―1.16%19.68%33.03%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
IN:JUBLPHARMAIN:JUBLPHARMA49NeutralINR 153.72B43.35―0.52%18.30%-44.95%

* General Sector Average

Performance Comparison

0%50%100%150%IN:SHILPAMEDIN:AKUMSIN:APLLTDIN:CAPLIPOINTIN:JUBLPHARMAIN:STARDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IN:SHILPAMED and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IN:SHILPAMEDShilpa Medicare Limited993.10614.24162.13%
IN:AKUMSAkums Drugs and Pharmaceuticals Limited740.55302.3268.99%
IN:APLLTDAlembic Pharmaceuticals Limited1029.7095.9010.27%
IN:CAPLIPOINTCaplin Point Laboratories Limited2386.50448.6823.15%
IN:JUBLPHARMAJubilant Pharmova Limited965.10-187.68-16.28%
IN:STARStrides Pharma Science Ltd1014.4070.627.48%

Shilpa Medicare Limited Corporate Events

Shilpa Medicare’s Jadcherla Unit Wins European GMP Nod

Oct 10, 2026

Shilpa Medicare Limited operates in the pharmaceutical industry, focusing on the manufacturing, testing and distribution of sterile injections and non-sterile tablet and capsule finished dosage forms. From its Unit 4 facility in Jadcherla, Telangana,...

Shilpa Medicare’s 39th AGM Confirms Clean Audit and Reviews Outlook

Sep 11, 2026

Shilpa Medicare Limited convened its 39th Annual General Meeting on September 11, 2026, via video conferencing and other audio-visual means from its registered office, adhering to guidelines issued by the Ministry of Corporate Affairs and SEBI. The m...

Shilpa Medicare Names Dr. Uday Harle CEO of Biologics Subsidiary

Aug 3, 2026

Shilpa Medicare Limited has appointed Dr. Uday N. Harle as Chief Executive Officer of its wholly owned subsidiary, Shilpa Biologicals Private Limited, effective August 3, 2026. The move signals a strengthening of leadership at the company’s biologics...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 19, 2026